VSTM, US92337C2035

Verastem stock heads toward November 5 results after $250 million offering

Published on 11/01/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verastem stock is due to report its latest quarterly results. The biotech focuses on medicines for RAS/MAPK-driven cancers.

Verastem approaches quarterly results

Verastem develops small-molecule medicines for cancers driven by the RAS/MAPK pathway.
The pipeline includes RAF/MEK, FAK and KRAS G12D inhibition programs.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem Oncology is heading toward its third-quarter 2026 financial update, scheduled for November 5. The company announced the reporting date on October 22, according to its investor relations website.

The release will give investors a fresh look at a biotech that is developing medicines for cancers driven by the RAS/MAPK pathway. Verastem's pipeline covers small-molecule programs targeting RAF/MEK, FAK and KRAS G12D signaling, according to the company.

Financing and pipeline shape outlook

Verastem also announced on October 14 the pricing of a 250 million US dollar offering of common stock and pre-funded warrants. The financing announcement and the upcoming results leave capital deployment and clinical development as key areas for investors to watch.

Verastem stock traded at 8.74 euros on Lang & Schwarz at 13:04 CEST on Saturday, October 31, 2026. Investors can follow the real-time quote of Verastem stock.